Publications by authors named "H M Verkade"
Objectives: To determine total, night- and daytime sleep duration and waking frequency among infants exclusively fed goat milk-based infant formula (GMF) or cow's milk-based infant formula (CMF) enroled in a randomised controlled trial and compare these to a human milk (HM) fed reference group.
Methods: Post hoc analysis from a double-blind randomised controlled trial in 304 healthy term infants was performed. Formula-fed infants were randomly assigned to receive exclusively GMF or CMF for a period of 112 days and compared to a reference group fed HM.
Background: Acute cellular rejection (ACR) remains a common complication causing significant morbidity post-liver transplantation. Non-human leukocyte antigen (non-HLA) mismatches were associated with an increased risk of ACR in kidney transplantation. Therefore, we hypothesized that donor-recipient non-HLA genetic mismatch is associated with increased ACR incidence post-liver transplantation.
View Article and Find Full Text PDFArticle Synopsis
- This study examined the effects of inhibiting adipose triglyceride lipase (ATGL) on the progression of metabolic dysfunction-associated steatohepatitis (MASH) and related liver fibrosis in mice on a high-fat diet.
- Mice treated with the ATGL inhibitor Atglistatin showed improvements in liver health, including lower liver enzymes and reduced lipid accumulation, revealing changes in gene expressions linked to liver and bile acid metabolism.
- The findings suggest that ATGL inhibition disrupts PPARα signaling pathways and alters bile acid synthesis, which may provide a therapeutic target for treating liver diseases associated with metabolic dysfunction.
Background: In patients with Alagille syndrome, cholestasis-associated clinical features can include high serum bile acids and severe pruritus that can necessitate liver transplantation. We aimed to evaluate the efficacy and safety of the ileal bile acid transporter inhibitor odevixibat versus placebo in patients with Alagille syndrome.
Methods: The ASSERT study was a phase 3, double-blind, randomised, placebo-controlled trial that enrolled patients at 21 medical centres or hospitals in ten countries (Belgium, France, Germany, Italy, Malaysia, the Netherlands, Poland, Türkiye, the UK, and the USA).